Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025

Human Chorionic Gonadotropin (hCG) Market Overview :

The global human chorionic gonadotropin (hCG) market generated a revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025. hCG hormone supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation. It can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. It is widely being used to treat infertility-related problems in women as well as increase sperm count in men. Moreover, it is used to treat cryptorchidism in young boys, a condition when the testicles have not dropped down into the scrotum normally.

Significant surge in infertility issues among men & women and increase in prevalence of hypogonadism in geriatric population drive the growth of the global hCG market. In addition, increase in awareness toward hCG among healthcare professionals and patients fuels the market growth. However, availability of substitutes and cautions & warnings issued by FDA against the side effects of hCG hamper the growth of the market. On the contrary, rise in popularity of fertility tourism and availability of advanced IVF facilities & treatment options are expected to provide lucrative opportunities for the market in the near future.

The global hCG market is segmented based on technology, therapeutic area, end user, and region. By technology, the market is bifurcated into natural source extraction and recombinant technology. Based on therapeutic area, it is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Depending on end user, it is segregated into fertility clinics, research institutions, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Human Chorionic Gonadotropin (hCG) Market :

The study provides an in-depth analysis of the global human chorionic gonadotropin (hCG) market along with the current trends and future estimations to elucidate the imminent investment pockets.

A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.

A qualitative analysis of driving factors and opportunities helps analyze the competitive scenario of the market.

Porter’s Five Forces analysis is provided to interpret the bargaining power of the suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.

Human Chorionic Gonadotropin (hCG) Key Market Segments :

    By Technology

        Natural Source Extraction

        Recombinant Technology

    By Therapeutic Area

        Female Infertility Treatment

        Male Hypogonadism

        Oligospermic Treatment

        Others

    By End User

        Fertility Clinics

        Research Institutions

        Others

    By Region

        North America

            U.S.

            Canada

            Mexico

        Europe

            Germany

            UK

            France

            Russia

            Rest of Europe

        Asia-Pacific

            Japan

            China

            India

            Australia

            Rest of Asia-Pacific

        LAMEA

            Brazil

            Turkey

            South Africa

            Saudi Arabia

            Rest of LAMEA

KEY MARKET PLAYERS

    Bristol Myers Squibb Company

    Merck & Co., Inc.

    Ferring B.V.

    Fresenius Kabi AG

    Cigna

    Sun Pharmaceutical Industries Ltd.

    Lee BioSolutions, Inc.

    Sanzyme

    Scripps Laboratories

    Lupin

The other players in the value chain include (profiles not included in the report):

    Kamiya Biomedical Company

    Intas Pharmaceuticals

    Prospec-Tany Technogene Ltd.

    Cipla Limited

    Biocare Medical LLC

    MyBioSource

    Zydus Cadila

    Life Medicare & Biotech Pvt. Ltd.

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key market benefits for stakeholders

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017

3.4. Porters five forces analysis

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. High risk of hypogonadism in geriatric population

3.5.1.2. Rise in infertility rates

3.5.1.3. Increase in awareness toward hCG among healthcare professionals and patients

3.5.2. Restraints

3.5.2.1. Availability of substitutes

3.5.2.2. Cautions & warnings issued by FDA against the side effects of hCG

3.5.3. Opportunity

3.5.3.1. Rise in popularity of fertility tourism

CHAPTER 4: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY

4.1. Overview

4.1.1. Market size and forecast

4.2. Natural source extraction

4.2.1. Key trends and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. Recombinant technology

4.3.1. Key trends and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

CHAPTER 5: HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA

5.1. Overview

5.1.1. Market size and forecast

5.2. Female infertility treatment

5.2.1. Market size and forecast

5.2.2. Market analysis, by country

5.3. Oligospermic treatment

5.3.1. Market size and forecast

5.3.2. Market analysis, by country

5.4. Male hypogonadism

5.4.1. Market size and forecast

5.4.2. Market analysis, by country

5.5. Others

5.5.1. Market size and forecast

5.5.2. Market analysis, by country

CHAPTER 6: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Fertility clinics

6.2.1. Market size and forecast, by region

6.2.2. Market analysis, by country

6.3. Research institutes

6.3.1. Market size and forecast, by region

6.3.2. Market analysis, by country

6.4. Others

6.4.1. Market size and forecast, by region

6.4.2. Market analysis, by country

CHAPTER 7: HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. North America market size and forecast, by country

7.2.2.1. U.S. market size and forecast, by technology

7.2.2.2. U.S. market size and forecast, by therapeutic area

7.2.2.3. U.S. market size and forecast, by end user

7.2.2.4. Canada market size and forecast, by technology

7.2.2.5. Canada market size and forecast, by therapeutic area

7.2.2.6. Canada market size and forecast, by end user

7.2.2.7. Mexico market size and forecast, by technology

7.2.2.8. Mexico market size and forecast, by therapeutic area

7.2.2.9. Mexico market size and forecast, by end user

7.2.3. North America market size and forecast, by technology

7.2.4. North America market size and forecast, by therapeutic area

7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany market size and forecast, by technology

7.3.2.2. Germany market size and forecast, by therapeutic area

7.3.2.3. Germany market size and forecast, by end user

7.3.2.4. UK market size and forecast, by technology

7.3.2.5. UK market size and forecast, by therapeutic area

7.3.2.6. UK market size and forecast, by end user

7.3.2.7. France market size and forecast, by technology

7.3.2.8. France market size and forecast, by therapeutic area

7.3.2.9. France market size and forecast, by end user

7.3.2.10. Rest of Europe market size and forecast, by technology

7.3.2.11. Rest of Europe market size and forecast, by therapeutic area

7.3.2.12. Rest of Europe market size and forecast, by end user

7.3.3. Europe market size and forecast, by technology

7.3.4. Europe market size and forecast, by therapeutic area

7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. Japan market size and forecast, by technology

7.4.2.2. Japan market size and forecast, by therapeutic area

7.4.2.3. Japan market size and forecast, by end user

7.4.2.4. China market size and forecast, by technology

7.4.2.5. China market size and forecast, by therapeutic area

7.4.2.6. China market size and forecast, by end user

7.4.2.7. India market size and forecast, by technology

7.4.2.8. India market size and forecast, by therapeutic area

7.4.2.9. India market size and forecast, by end user

7.4.2.10. Australia market size and forecast, by technology

7.4.2.11. Australia market size and forecast, by therapeutic area

7.4.2.12. Australia market size and forecast, by end user

7.4.2.13. Rest of Asia-Pacific market size and forecast, by technology

7.4.2.14. Rest of Asia-Pacific market size and forecast, by therapeutic area

7.4.2.15. Rest of Asia-Pacific market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by technology

7.4.4. Asia-Pacific market size and forecast, by therapeutic area

7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities

7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Brazil market size and forecast, by technology

7.5.2.2. Brazil market size and forecast, by therapeutic area

7.5.2.3. Brazil market size and forecast, by end user

7.5.2.4. Turkey market size and forecast, by technology

7.5.2.5. Turkey market size and forecast, by therapeutic area

7.5.2.6. Turkey market size and forecast, by end user

7.5.2.7. Saudi Arabia market size and forecast, by technology

7.5.2.8. Saudi Arabia market size and forecast, by therapeutic area

7.5.2.9. Saudi Arabia market size and forecast, by end user

7.5.2.10. South Africa market size and forecast, by technology

7.5.2.11. South Africa market size and forecast, by therapeutic area

7.5.2.12. South Africa market size and forecast, by end user

7.5.2.13. Rest of LAMEA market size and forecast, by technology

7.5.2.14. Rest of LAMEA market size and forecast, by therapeutic area

7.5.2.15. Rest of LAMEA market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by technology

7.5.4. LAMEA market size and forecast, by therapeutic area

7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

8.1. Bristol Myers Squibb Company

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Business performance

8.2. Ferring Pharmaceuticals Inc.

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Operating business segments

8.2.4. Product portfolio

8.3. Merck & Co., Inc.

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segments

8.3.4. Product portfolio

8.3.5. Business performance

8.4. Fresenius Kabi AG

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Product portfolio

8.4.4. Business performance

8.5. Cigna

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Business performance

8.6. Sun Pharmaceutical Industries Ltd.

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Operating business segments

8.6.4. Product portfolio

8.6.5. Business performance

8.7. Lee BioSolutions Inc.

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Product portfolio

8.8. Sanzyme

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Product portfolio

8.9. Scripps Laboratories

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.10. LUPIN

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product portfolio

8.10.5. Business performanc

TABLE 01. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 02. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR NATURAL SOURCE EXTRACTION, BY REGION, 2017-2025 ($MILLION)

TABLE 03. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RECOMBINANT TECHNOLOGY, BY REGION, 2017-2025 ($MILLION)

TABLE 04. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 05. HUMAN CHORIONIC GONADOTROPIN MARKET FOR FEMALE INFERTILITY TREATMENT, BY REGION, 2017-2025 ($MILLION)

TABLE 06. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OLIGOSPERMIC TREATMENT, BY REGION, 2017-2025 ($MILLION)

TABLE 07. HUMAN CHORIONIC GONADOTROPIN MARKET FOR MALE HYPOGONADISM, BY REGION, 2017-2025 ($MILLION)

TABLE 08. HUMAN CHORIONIC GONADOTROPIN MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)

TABLE 09. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 10. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR FERTILITY CLINICS, BY REGION, 2017-2025 ($MILLION)

TABLE 11. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RESEARCH INSTITUTES, BY REGION, 2017-2025 ($MILLION)

TABLE 12. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR OTHERS, BY REGION, 2017-2025 ($MILLION)

TABLE 13. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY REGION, 2017-2025 ($MILLION)

TABLE 14. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)

TABLE 15. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 16. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 17. U.S. HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 18. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 19. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 20. CANADA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 21. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 22. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 23. MEXICO HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 24. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 25. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 26. NORTH AMERICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 27. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)

TABLE 28. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 29. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 30. GERMANY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 31. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 32. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 33. UK HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 34. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 35. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 36. FRANCE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 37. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 38. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 39. REST OF EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 40. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 41. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 42. EUROPE HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 43. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)

TABLE 44. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 45. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 46. JAPAN HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 47. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 48. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 49. CHINA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 50. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 51. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 52. INDIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 53. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 54. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 55. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 56. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 57. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 58. REST OF ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 59. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 60. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 61. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 62. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY COUNTRY, 2017-2025 ($MILLION)

TABLE 63. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 64. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 65. BRAZIL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 66. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 67. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 68. TURKEY HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 69. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 70. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 71. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 72. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 73. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 74. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 75. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 76. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 77. REST OF LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 78. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY TECHNOLOGY, 2017-2025 ($MILLION)

TABLE 79. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY THERAPEUTIC AREA, 2017-2025 ($MILLION)

TABLE 80. LAMEA HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET, BY END USER, 2017-2025 ($MILLION)

TABLE 81. BRISTOL MYERS: COMPANY SNAPSHOT

TABLE 82. FERRING: COMPANY SNAPSHOT

TABLE 83. FERRING: OPERATING SEGMENTS

TABLE 84. FERRING: PRODUCT PORTFOLIO

TABLE 85. MERCK: COMPANY SNAPSHOT

TABLE 86. MERCK: OPERATING SEGMENTS

TABLE 87. MERCK: PRODUCT PORTFOLIO

TABLE 88. FRESENIUS: COMPANY SNAPSHOT

TABLE 89. FRESENIUS: PRODUCT PORTFOLIO

TABLE 90. CIGNA: COMPANY SNAPSHOT

TABLE 91. CIGNA: OPERATING SEGMENTS

TABLE 92. SUN PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 93. SUN PHARMA: PRODUCT PORTFOLIO

TABLE 94. LEE: COMPANY SNAPSHOT

TABLE 95. LEE: PRODUCT SEGMENTS

TABLE 96. LEE: PRODUCT PORTFOLIO

TABLE 97. SANZYME: COMPANY SNAPSHOT

TABLE 98. SANZYME: PRODUCT SEGMENTS

TABLE 99. SANZYME: PRODUCT PORTFOLIO

TABLE 100. SCRIPPS: COMPANY SNAPSHOT

TABLE 101. SCRIPPS: PRODUCT SEGMENTS

TABLE 102. SCRIPPS: PRODUCT PORTFOLIO

TABLE 103. LUPIN: COMPANY SNAPSHOT

TABLE 104. LUPIN: PRODUCT PORTFOLIO FIGURE 01. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET SEGMENTATION

FIGURE 02. TOP INVESTMENT POCKETS, 2017

FIGURE 03. TOP PLAYER POSITIONING, 2017

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. HIGH BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTION

FIGURE 07. HIGH THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE COMPETITIVE RIVALRY

FIGURE 09. GLOBAL HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY

FIGURE 10. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR NATURAL SOURCE EXTRACTION, BY COUNTRY, 2017 & 2025 (%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RECOMBINANT TECHNOLOGY, BY COUNTRY, 2017 & 2025 (%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR FEMALE INFERTILITY TREATMENT, BY COUNTRY, 2017 & 2025 (%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR OLIGOSPERMIC TREATMENT, BY COUNTRY, 2017 & 2025 (%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR MALE HYPOGONADISM, BY COUNTRY, 2017 & 2025 (%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 (%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR FERTILITY CLINICS, BY COUNTRY, 2017 & 2025 (%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2017 & 2025 (%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HUMAN CHORIONIC GONADOTROPIN (HCG) MARKET FOR OTHERS, BY COUNTRY, 2017 & 2025 (%)

FIGURE 19. BRISTOL-MYERS SQUIBB: REVENUE, 2015-2017 ($MILLION)

FIGURE 20. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)

FIGURE 21. MERCK: REVENUE, 2015-2017 ($MILLION)

FIGURE 22. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 23. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 24. FRESENIUS: REVENUE, 2015-2017 ($MILLION)

FIGURE 25. FRESENIUS: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 26. FRESENIUS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 27. CIGNA: NET SALES, 2016-2018 ($MILLION)

FIGURE 28. CIGNA: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 29. SUN PHARMA: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 30. SUN PHARMA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

FIGURE 31. LUPIN: NET SALES, 2015-2017 ($MILLION)

FIGURE 32. LUPIN: REVENUE SHARE BY GEOGRAPHY, 2017 (%